(Reuters) – Immunitybio Inc said on Thursday the U.S. Food and Drug Administration declined to approve its marketing application for a type of bladder cancer treatment.
(Reporting by Sriparna Roy in Bengaluru)
US FDA declines to approve Immunitybio for bladder cancer treatment
May 11, 2023 | 7:12 AM
